CytomX Therapeutics
CTMX
CytomX Therapeutics (CTMX) analyst forecast and price target
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| JP Morgan | Maintained | Overweight | $11.00 from $12.00 | Aug 13, 2026 |
| Guggenheim | Maintained | Buy | $14.00 from $15.00 | Aug 10, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $11.00 from $17.00 | May 11, 2026 |
| Piper Sandler | Maintained | Overweight | $12.00 from $10.00 | Mar 23, 2026 |
| Barclays | Maintained | Overweight | $16.00 from $10.00 | Mar 19, 2026 |
| Guggenheim | Maintained | Buy | $15.00 from $10.00 | Mar 18, 2026 |
| Jefferies | Maintained | Buy | $16.00 from $8.00 | Mar 18, 2026 |
| Wedbush | Maintained | Outperform | $11.00 from $6.00 | Mar 17, 2026 |
| JP Morgan | Upgraded | Neutral → Overweight | $12.00 from $7.00 | Mar 16, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $17.00 from $10.00 | Mar 16, 2026 |
| Guggenheim | Maintained | Buy | $10.00 | Mar 9, 2026 |
| Barclays | Maintained | Overweight | $10.00 from $8.00 | Feb 4, 2026 |
| Cantor Fitzgerald | Maintained | Overweight | $10.00 from $6.00 | Feb 4, 2026 |
| Piper Sandler | Maintained | Overweight | $10.00 from $6.50 | Jan 20, 2026 |
| Barclays | Maintained | Overweight | $8.00 from $6.00 | Jan 20, 2026 |
| Guggenheim | Initiated Coverage | Buy | $10.00 | Jan 20, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $10.00 from $5.00 | Nov 11, 2025 |
| Barclays | Maintained | Overweight | $6.00 from $3.50 | Oct 21, 2025 |
| Cantor Fitzgerald | Initiated Coverage | Overweight | $6.00 | Sep 22, 2025 |
| Barclays | Initiated Coverage | Overweight | $3.50 | Sep 17, 2025 |
Frequently asked questions
What is the latest analyst rating on CTMX?
On Aug 13, 2026, JP Morgan maintained CytomX Therapeutics at Overweight with a price target of $11.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.